Hostname: page-component-77c89778f8-5wvtr Total loading time: 0 Render date: 2024-07-19T08:08:38.468Z Has data issue: false hasContentIssue false
  • English
  • Français

63 Psychosis and Parkinson's disease

Published online by Cambridge University Press:  24 June 2014

Tomislav Peharda ,
Eva Zorijan ,
Ivica Šain  and
Dragutin Breški
Tomislav Peharda
Affiliation:
Psychiatry, OB Pula Zagrebačka 30, 52100 Pula, Croatia, E-mail: evazorijan@yahoo.com
Eva Zorijan
Affiliation:
Psychiatry, OB Pula Zagrebačka 30, 52100 Pula, Croatia, E-mail: evazorijan@yahoo.com
Ivica Šain
Affiliation:
Psychiatry, OB Pula Zagrebačka 30, 52100 Pula, Croatia, E-mail: evazorijan@yahoo.com
Dragutin Breški
Affiliation:
Psychiatry, OB Pula Zagrebačka 30, 52100 Pula, Croatia, E-mail: evazorijan@yahoo.com
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.
Type
Posters – Psychiatry
Information
Acta Neuropsychiatrica , Volume 21 , Issue S2: Special Issue: Abstracts of 49th Neuropsychiatric Pula Congress, 17-20 June 2009, Pula, Croatia , June 2009 , pp. 93
Copyright
Copyright © 2009 John Wiley & Sons A/S

Introduction/Objectives:

Psychosis in Parkinson's disease can be caused by both extrinsic and intrinsic factors.

Participants, Materials/Methods:

Case presentation: In the period from 1982 to 1986 the patient S.A. (75-year-old woman) had been hospitalized several times. She was admitted to the psychiatry with the diagnosis psychosis depressive and cured with antipsychotics (clozapine, levomepromazin) and antidepressants (maprotilin). In 2009 she was again admitted, but this time in the semistuporous state, mutistic, with the clinical state of paranoid – halucinatory psychosis. She was diagnosed Parkinson's disease 2 years ago and has been treated with the combination of levodopa and benzerazid as well as entekapon.

Results:

The question is whether the trigger for the psychosis is Parkinson's disease, antiparkinsonian medications in itself, or the previous psychiatric diagnosis represents the risk factor which enables the antiparkinsonian medications to activate the psychosis. The treatment involved gradual decrease in the dosage of antiparkinsonian medications and introduction of antipsychotics (clozapine).